Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

It seems to me that @Biohazard3737 (“Sheep of Wall Street”) is drawing a negative inference about EDP-235 based on the technical details of the potency assays used by ENTA without his considering alternative explanations for the way the assays were conducted. Only people inside ENTA would know the rationale for these details, as far as I can tell.

Regarding RSV, @Biohazard3737 evidently does not understand that the MoA of EDP-938 (an N-protein inhibitor) is intended to work later in the course of an infection than a fusion inhibitor. Of course, the RSVP trial might fail to meet its primary endpoint, but if that happens it won’t be for the reason cited by @Biohazard3737.